Documentary about the rationing of expensive cancer drugs by the National Institute for Health and Clinical Excellence.
Due to limited budgets, the NHS cannot afford to provide all the treatments on the market. So how do you decide which drugs to offer?
Adam Wishart follows policy makers, the National Institute for Health and Clinical Excellence, patients in need of life-extending treatments, and the U.S. companies that discovered it and would benefit from it, following the heart-wrenching unprecedented exposure to a drug decision.
As the body that determines affordable drug treatment in the NHS, the National Institute for Health and Clinical Excellence wields enormous power over many patients in the UK.
This insightful documentary from director Adam Wishart focuses on the cancer drug Revlimid and offers an introduction to a senior member of the Institute and those who will be affected by its decision, such as cancer patients and the NHS Managers) delivered a speech.
